公开(公告)号：US11958859B2

公开(公告)日：2024-04-16

申请号：US16964804

申请日：2019-01-24

Applicant: Florida Gulf Coast University Board of Trustees

Inventor： Gregory R. Boyce

IPC: C07D491/048 ,  A23G4/08 ,  A61K8/06 ,  C07C57/44 ,  C07C309/17

CPC classification number: C07D491/048 ,  A23G4/08 ,  A61K8/06 ,  C07C57/44 ,  C07C309/17

Abstract: A pro-fragrance delivery system based on a vitamin scaffold and a fragrant alcohol. The vitamin scaffold may be a vitamer of vitamin B6 or derivatives thereof. The pro-fragrance releases the fragrant alcohol by action of water at neutral pH.

公开(公告)号：US20240116944A1

公开(公告)日：2024-04-11

申请号：US18388765

申请日：2023-11-10

Applicant: University of Utah Research Foundation

Inventor： Darrell Davis ,  Shuanghu Liu

IPC: C07D491/147 ,  C07D235/30 ,  C07D487/04 ,  C07D491/048 ,  C07D491/052 ,  C07D495/14

CPC classification number: C07D491/147 ,  C07D235/30 ,  C07D487/04 ,  C07D491/048 ,  C07D491/052 ,  C07D495/14

Abstract: The present disclosure is concerned with benzimidazole compounds and methods of using these compounds for the treatment of hepatitis (e.g., hepatitis C), RNA virus infections (e.g., Zika virus, dengue virus, Powassan virus, Chikungunya virus, Enterovirus, respiratory syntactical virus (RSV), Rift Valley fever, Influenza virus, Tacaribe virus, Mayaro virus, West Nile virus, yellow fever virus, and coronavirus), and disorders of uncontrolled cellular proliferation (e.g., cancer). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20240116943A1

公开(公告)日：2024-04-11

申请号：US18124389

申请日：2023-03-21

Applicant: Japan Tobacco Inc.

Inventor： Masafumi Inoue ,  Yosuke Ogoshi ,  Takayuki Furukawa ,  Takuya Machida ,  Ikuo Mitani ,  Kazuhito Harada ,  Yuichi Nakagawa ,  Nobutaka Yamaoka

IPC: C07D491/048

CPC classification number: C07D491/048

Abstract: The present invention provides a compound having a Pim-1 inhibitory activity.
The present invention provides a compound of Formula [I] or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same, and a pharmaceutical use thereof, and the like.




wherein each symbol is as defined in the description.

公开(公告)号：US11957049B2

公开(公告)日：2024-04-09

申请号：US16020883

申请日：2018-06-27

Applicant: SAMSUNG DISPLAY CO., LTD.

Inventor： Stefan Seifermann

IPC: C07D401/14 ,  C07D209/86 ,  C07D209/88 ,  C07D403/10 ,  C07D403/14 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  C09K11/06 ,  H10K50/11 ,  H10K50/12 ,  H10K50/15 ,  H10K50/16 ,  H10K50/17 ,  H10K50/18 ,  H10K85/60 ,  H10K50/125 ,  H10K85/00 ,  H10K101/10 ,  H10K101/40

CPC classification number: H10K85/6572 ,  C07D209/86 ,  C07D209/88 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  C09K11/06 ,  H10K50/12 ,  H10K50/15 ,  H10K50/16 ,  H10K50/171 ,  H10K50/18 ,  H10K85/654 ,  C09K2211/1007 ,  C09K2211/1011 ,  C09K2211/1029 ,  H10K50/11 ,  H10K50/125 ,  H10K85/00 ,  H10K2101/10 ,  H10K2101/40 ,  Y02E10/549

Abstract: The invention relates to an organic molecule, in particular for use in optoelectronic devices. According to the invention, the organic molecule consists of

a first chemical moiety with a structure of formula I,






and

two second chemical moieties, each at each occurrence independently with a structure of formula II,






wherein the first chemical moiety is linked to each of the two second chemical moieties via a single bond;

wherein

T, V is independently the binding site of a single bond linking the first chemical moiety to one of the two second chemical moieties or is hydrogen;

W, X, Y is independently the binding site of a single bond linking the first chemical moiety to one of the two second chemical moieties or is selected from the group consisting of hydrogen, CN and CF3.

公开(公告)号：US20240092764A1

公开(公告)日：2024-03-21

申请号：US18240293

申请日：2023-08-30

Applicant: Insilico Medicine IP Limited

Inventor： Aleksandr Aliper ,  Vladimir Aladinskiy ,  Aleksandrs Zavoronkovs

IPC: C07D405/04 ,  A61K31/4164 ,  A61K31/4439 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048

CPC classification number: C07D405/04 ,  A61K31/4164 ,  A61K31/4439 ,  A61K31/506 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048

Abstract: A TNIK and/or MAP4K4 kinase inhibitor can include: Formula A, derivative, prodrug, salt, stereoisomer, tautomer polymorph, or solvate thereof, or having chirality at any chiral center,






wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y1 is a linker; each n is independently 0, 1, or 2; each o is independently 0, 1, 2, 3, 4, or 5; each R1, R6, R11, and R12 is independently a substituent; and RA is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.

公开(公告)号：US20240092760A1

公开(公告)日：2024-03-21

申请号：US18334325

申请日：2023-06-13

Applicant: IMMUNESENSOR THERAPEUTICS, INC. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Jian QIU ,  Qi WEI ,  Matt TSCHANTZ ,  Heping SHI ,  Youtong WU ,  Huiling TAN ,  Lijun SUN ,  Chuo CHEN ,  Zhijian CHEN

IPC: C07D401/14 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07F9/6503 ,  C07F9/6506

CPC classification number: C07D401/14 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07F9/65031 ,  C07F9/6506

Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

公开(公告)号：US20240083873A1

公开(公告)日：2024-03-14

申请号：US18028213

申请日：2021-11-03

Applicant: SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD

Inventor： Yuanshan Yao ,  Guozhong Ye ,  Linbo Luan ,  Yongkai Chen ,  Chaodong Wang

IPC: C07D401/14 ,  C07D491/107 ,  C07D491/048 ,  C07D487/10 ,  C07D519/00

CPC classification number: C07D401/14 ,  C07D491/107 ,  C07D491/048 ,  C07D487/10 ,  C07D519/00

Abstract: Disclosed are a pyrimidine carboxamide compound and an application thereof. Further provided are a pyrimidine carboxamide compound represented by formula (I), or a tautomer, mesomer, racemate, enantiomer, or diastereomer thereof, a mixture form thereof, or a pharmaceutically acceptable salt thereof. The compound can be used as a Vanin enzyme inhibitor, and can be used to prepare a drug for treating various diseases, including Crohn's disease, ulcerative colitis, and so on.

公开(公告)号：US11895915B2

公开(公告)日：2024-02-06

申请号：US16521369

申请日：2019-07-24

Applicant: LG Display Co., Ltd. ,  LG CHEM, LTD.

Inventor： Hyong-Jong Choi ,  Tae-Ryang Hong ,  Joong-Hwan Yang ,  Jun-Yun Kim ,  Wan-Pyo Hong ,  Jin-Joo Kim ,  Hong-Sik Yoon

IPC: H10K85/60 ,  C07D405/14 ,  C09K11/06 ,  C07D409/04 ,  C07D491/048 ,  C07D487/04 ,  H10K50/11 ,  H10K101/10 ,  H10K101/30 ,  H10K101/40 ,  C07D409/14

CPC classification number: H10K85/6572 ,  C07D405/14 ,  C07D409/14 ,  C07D487/04 ,  C07D491/048 ,  C09K11/06 ,  H10K85/615 ,  H10K85/657 ,  H10K85/6574 ,  H10K85/6576 ,  C09K2211/1018 ,  H10K50/11 ,  H10K2101/10 ,  H10K2101/30 ,  H10K2101/40

Abstract: Disclosed is an organic light emitting diode (OLED) comprising at least one emitting unit that includes a first compound, which may have a bipolar property, a second compound, which may have a delayed fluorescent property, and a third compound, which may have narrow FWHM (full width at half maximum) and a fluorescent property, and an organic light emitting device including the OLED. Further the compounds have defined relative LUMO and HOMO energies. The OLED and the organic light emitting device has enhanced luminous efficiency, color purity and luminous life span as well as low driving voltage.

公开(公告)号：US20240025883A1

公开(公告)日：2024-01-25

申请号：US18455029

申请日：2023-08-24

Applicant: Hoffmann-La Roche Inc.

Inventor： Guido GALLEY ,  Luca GOBBI ,  Wolfgang GUBA ,  Dmitry MAZUNIN ,  Emmanuel PINARD ,  Antonio RICCI

IPC: C07D403/12 ,  C07D409/12 ,  C07D495/04 ,  C07D471/04 ,  C07D405/14 ,  C07D491/048 ,  C07D513/04

CPC classification number: C07D403/12 ,  C07D409/12 ,  C07D495/04 ,  C07D513/04 ,  C07D405/14 ,  C07D491/048 ,  C07D471/04

Abstract: Compounds having the general formula I




wherein R1, R2, R3, R4, X1 and X2 are as described herein, composition including the compounds and methods of using the compounds for treatment of GPR17-mediated diseases.

公开(公告)号：US20240018141A1

公开(公告)日：2024-01-18

申请号：US18236004

申请日：2023-08-21

Applicant: Regents of the University of Minnesota

Inventor： David M. FERGUSON ,  Peter Gustav LARSON

IPC: C07D471/04 ,  C07D513/04 ,  C07D491/048 ,  A61P37/04

CPC classification number: C07D471/04 ,  C07D513/04 ,  C07D491/048 ,  A61P37/04

Abstract: The present disclosure provides compounds of Formula I: (I), pharmaceutically acceptable salts thereof, conjugates thereof, as well as methods of synthesizing and using such compounds, e.g., in a method of treating a pathological condition in a subject. The compounds described herein can have immunomodulatory properties and can interact with a Toll-like receptor as described herein.